Background: Catheter ablation is an established rhythm-control strategy for atrial fibrillation (AF), yet peri-procedural embolic stroke may still occur despite uninterrupted NOAC therapy. Case presentation: A 49-year-old woman on dabigatran developed acute ischemic stroke three days after AF ablation, presenting with left hemiparesis and dysarthria. Idarucizumab (5 g) enabled safe intravenous thrombolysis followed by emergency endovascular thrombectomy (EVT), achieving complete recanalization (mTICI 3). Angiography revealed an incidental 7 mm right MCA aneurysm at the occlusion site. Dabigatran was resumed on day 4, and one month later, the aneurysm was successfully treated with stent-assisted coil embolization. She remained asymptomatic at two months. Conclusions: This case illustrates how idarucizumab reversal expands reperfusion options by enabling both IVT and EVT in NOAC-treated patients and highlights the diagnostic role of EVT in revealing underlying vascular pathology, emphasizing the need for individualized post-procedural antithrombotic management.
8 October 2026 in Frontiers in Rehabilitation Sciences
Introduction: Robotic-assisted therapy (RAT) has emerged as a promising intervention for post-stroke recovery; however, its implementation in developing countries such as Indonesia remains limited by economic, technical, and systemic barriers. This structured narrative review summarizes clinical effect reported by systematics review and meta-analyses and examines implementation consideration and potential economic feasibility within the Indonesian healthcare context. Method: A structured review of systematic reviews and meta-analyses (2015–2025) was conducted using PubMed, Scopus, PEDro, and Cochrane Library. Studies involving adult with stroke were included. Findings were synthesized narratively because of heterogeneity. Implementation barriers were analyzed, and a scenario-based economic model was developed to assess feasibility of RAT in Indonesia. QALY-equivalent outcomes (QEOs) were estimated using ratio-based value-transfer approach that scaled published reference values according to observed functional effects. Result: Evidence from 22 systematic reviews indicated that RAT improved functional outcomes compared with conventional therapy, particularly gait and upper-limb function (effect sizes: 0.02–0.52). Key implementation barriers included limited device availability, inadequate workforce training, and regulatory constraints. Modelled ICERs ranged from US$236.23–752.31 per QEO for upper-limb rehabilitation and US$558.86–4,890 per QEO for gait-related rehabilitation. Most estimates remained below the Indonesian willingness-to-pay threshold (<US$5,030), suggesting a favourable economic profile under model assumptions, particularly in higher-resource provinces, while lower-income regions may face affordability constraints. Conclusion: RAT shows potential clinical benefits, but implementation in Indonesia should consider clinical effectiveness, economic feasibility, infrastructure, workforce, technology acceptance, and reimbursement. A phased approach in suitable tertiary-care settings may support wider adoption based on local evidence.